Preliminary stability studies of a ss-SARS-CoV-2 virus-like particle vaccine

Preliminary studies demonstrate that a beta-SARS-CoV-2 virus-like particle vaccine maintains structural integrity and immunogenicity at 4°C for 14 days and at -80°C for up to two years, with stability significantly enhanced by excipients such as polysorbate 80, sorbitol, or L-histidine compared to PBS alone.

The Gist

Imagine you've built a tiny, perfect model of a virus—a "ghost" version that looks exactly like the real SARS-CoV-2 virus but has no engine inside, so it can't make anyone sick. This is your Vaccine.

Now, imagine you need to ship this delicate model across the world to protect people. The problem? These models are fragile. If they get too hot, or if they sit in a bottle too long, they might crumble, stick together, or lose their shape. If they lose their shape, your immune system won't recognize them, and the vaccine won't work.

This paper is essentially a stability test to see how well these "ghost virus" models hold up under different conditions and if adding certain "packing materials" (called excipients) helps keep them safe.

Here is the breakdown of their experiment using simple analogies:

1. The Goal: Keeping the "Ghost" Intact

The researchers made Virus-Like Particles (VLPs). Think of these as 3D puzzles made of the virus's outer shell (the Spike, Envelope, and Membrane proteins).

• The Challenge: If the puzzle pieces fall apart or the whole structure collapses, the vaccine is useless.
• The Question: Can we keep these puzzles intact for months or even years without them breaking?

2. The "Packing Materials" (Excipients)

The team tried adding three different types of "packing peanuts" to the vaccine bottle to see which one protected the puzzle best:

• Polysorbate 80 (PS80): Think of this as a non-stick coating. It stops the virus particles from sticking to the sides of the bottle or clumping together like wet sand.
• Sorbitol: This is a type of sugar. Think of it as a cushion. It surrounds the virus particles and protects them from the stress of temperature changes, kind of like bubble wrap.
• L-Histidine: This is an amino acid. Think of it as a pH stabilizer or a "buffer" that keeps the environment inside the bottle just right, preventing the particles from getting angry and falling apart.

3. The Experiments: The Stress Tests

The researchers put these vaccines in different "weather conditions" to see how long they lasted:

• The Refrigerator Test (4°C): They left the vaccines in a fridge for 14 days.
  • Without packing materials: The vaccine started to lose its "spark" (antigenicity) after a week. It was like a flower wilting.
  • With packing materials: The vaccines stayed fresh! The Sorbitol (sugar) worked the best, keeping the vaccine looking and acting like new for the full two weeks.
• The Freezer Test (-30°C and -80°C): They put the vaccines in deep freezers.
  • The Result: Wow! The vaccines stored at -80°C (a super-cold freezer) stayed perfect for 2 years. It's like putting a time capsule in a deep freeze; when they took it out, it was still in perfect condition.

4. How Did They Check? (The Tools)

They didn't just guess; they used three high-tech ways to inspect the "ghosts":

1. ELISA (The ID Check): They used a special antibody "handshake" to see if the virus still looked like a virus. If the handshake happened, the vaccine was still good.
2. Western Blot (The X-Ray): They took a picture of the protein pieces to make sure none of them had broken into tiny, useless fragments. The pieces were all still the right size.
3. Dynamic Light Scattering (DLS) (The Size Check): They shone a laser through the liquid to measure the size of the particles.
   • The Good News: The particles stayed the same size and didn't clump together. They remained as distinct, individual "ghosts" rather than a big, messy blob.

5. The Big Takeaway

This study is like a dress rehearsal for a major vaccine launch.

• The Good News: The vaccine is tough. It can survive in a fridge for weeks and in a deep freezer for years.
• The Secret Weapon: Adding simple, cheap ingredients like sugar (sorbitol) or non-stick agents (PS80) makes the vaccine much more stable.
• Why it Matters: Right now, many vaccines need constant refrigeration or frequent "boosters" because immunity fades. If this VLP vaccine is stable and long-lasting, it could be a game-changer. It could be shipped to remote areas without needing a super-cold chain, and it might protect people for much longer, reducing the need for constant booster shots.

In a nutshell: The researchers built a safe, fake virus, tested how to keep it from breaking, and found that with a little bit of sugar and non-stick coating, it can stay fresh for a very long time. This is a huge step toward making a better, more durable vaccine for the future.

Technical Summary

1. Problem Statement

• Limitations of Current Vaccines: While mRNA/LNP vaccines were critical in controlling the pandemic, they suffer from short-lived immune responses, necessitating frequent boosters and rapid re-development for emerging variants.
• Vaccine Stability Challenges: Virus-like particle (VLP) vaccines offer a promising alternative with the potential for longer-lasting immunity. However, for VLPs to be viable as commercial vaccines, they must maintain structural integrity and conformational stability during long-term storage. Degradation, aggregation, or conformational changes can lead to loss of potency and batch-to-batch variability, hindering licensure.
• Knowledge Gap: There is a need to characterize the stability of specific SARS-CoV-2 VLP formulations under various storage conditions and with specific stabilizing excipients to ensure they meet industry standards for shelf-life and quality.

2. Methodology

The study utilized a ß-SARS-CoV-2 VLP vaccine composed of self-cleaving polyproteins expressing the Spike (S), Envelope (E), and Membrane (M) structural proteins.

• Production & Purification:
  • VLPs were produced in Vero cells using recombinant adenovirus vectors.
  • Purification involved a sequential process: Tangential Flow Filtration (TFF), diafiltration, anion exchange chromatography, ultrafiltration, and sterile filtration (0.45µm).
• Experimental Design:
  • Storage Conditions: VLPs were stored at 4°C (short-term stability) and -30°C / -80°C (long-term stability).
  • Excipients Tested: The study evaluated three stabilizing agents at concentrations mimicking commercial vaccines (MMR, HPV):
    • Polysorbate 80 (PS80): 0.01% w/v (non-ionic surfactant).
    • Sorbitol: 1.2% w/v (sugar).
    • L-histidine: 0.16% w/v (amino acid).
  • Control: VLPs stored in PBS alone (with physiological NaCl at 137mM).
• Analytical Assays:
  • ELISA: Used to assess antigenicity and binding to anti-Spike (S) and anti-Receptor Binding Domain (RBD) antibodies.
  • Western Immunoblot: Used to verify the presence and molecular weight of S, E, and M proteins over time.
  • Dynamic Light Scattering (DLS): Used to measure particle size, size distribution, and polydispersity to detect aggregation or structural degradation.

3. Key Contributions

• Formulation Optimization: The study systematically evaluated the efficacy of specific excipients (PS80, sorbitol, L-histidine) in stabilizing SARS-CoV-2 VLPs, identifying that these additives significantly outperform PBS alone.
• Multi-Modal Validation: The research combined immunological assays (ELISA, Western blot) with biophysical characterization (DLS) to provide a comprehensive view of both antigenic integrity and physical particle structure.
• Long-Term Stability Data: The study provides preliminary data suggesting that these VLPs can remain stable for up to 2 years when stored at -80°C, a critical metric for global distribution and stockpiling.

4. Key Results

• Short-Term Stability (4°C for 14 Days):
  • Control (PBS): VLPs in PBS alone showed a waning of antigenicity after 7 days and were weakly reactive by day 14.
  • Excipients: All three excipients improved stability. Sorbitol exhibited the best stability, maintaining strong reactivity through day 14. PS80 and L-histidine also maintained stability better than the control.
  • Protein Integrity: Western blots confirmed that S (115 kDa), M (25 kDa), and E (24 kDa dimer) proteins remained intact with no size changes or degradation over 14 days in all formulations.
  • Particle Structure: DLS analysis showed VLPs maintained a polydisperse distribution with two peaks (183 nm for intact VLPs and 12 nm for free spike trimers). The Polydispersity Index (PDI) remained below 0.1, indicating high uniformity and no significant aggregation in any formulation.
• Long-Term Stability:
  • Storage at -30°C for 4 months retained strong anti-RBD binding.
  • Storage at -80°C for 24 months (2 years) maintained the DLS profile and size distribution, confirming long-term structural integrity.

5. Significance

• Vaccine Development: These findings validate the feasibility of developing a SARS-CoV-2 VLP vaccine with a robust shelf-life. The ability to store the vaccine at 4°C for at least two weeks (with excipients) and at -80°C for years addresses critical logistical challenges in vaccine distribution.
• Immunogenicity Preservation: The maintenance of antigenicity (ELISA) and particulate structure (DLS) suggests that the VLPs will likely retain their ability to stimulate protective immune responses (both antibody and T-cell) after storage.
• Regulatory Pathway: The data provides a methodological framework for quality control and batch testing, which is essential for progressing the vaccine to clinical trials and eventual licensure.
• Future Directions: While the results are promising, the authors note that further studies using advanced techniques (e.g., Asymmetric Flow Field-Flow Fractionation) and combinations of excipients are needed to fully characterize the vaccine for regulatory submission.

In conclusion, the study demonstrates that the ß-SARS-CoV-2 VLP vaccine is structurally and immunologically stable, particularly when formulated with sorbitol, PS80, or L-histidine, offering a stable alternative to current mRNA-based platforms.